<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144504">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01754285</url>
  </required_header>
  <id_info>
    <org_study_id>LF-PB/11/04</org_study_id>
    <nct_id>NCT01754285</nct_id>
  </id_info>
  <brief_title>Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea</brief_title>
  <official_title>A Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of LF-PB 10 mg, 20 mg, and 30 mg to Treat Lymphorrhea Post Axillary Dissection in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chemi S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chemi S.p.A.</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, multicenter, double-blind, double-dummy, parallel-group,
      placebo-controlled, study to evaluate LF-PB versus placebo in female patients with brest
      cancer who are undergoing breast surgery with axillary lymphnode dissection.

      Recruited patients will be randomly assigned to one of the following treatment groups:
      Placebo, LF-PB 10 mg, LF-PB 20 mg and LF-PB 30 mg.

      Mode of administration is single intramuscular (IM) injection so the treatments arms are as
      follows:

      Placebo:  2 injections of placebo LF-PB 10 mg:  2 injections = placebo + 10 mg LF-PB 20 mg:
      2 injections = placebo + 20 mg LF-PB 30 mg:  2 injections = 10 mg + 20 mg

      The study will randomize a total of 120 patients (30 per arm) in about 10 Italian Sites.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>effect of LF-PB 10 mg, 20 mg, and 30 mg on time to resolution of lymphorrhea;</measure>
    <time_frame>12 weeks post surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>End of lymphorrhea will be declared when the lymph volume measured by the patient is &lt; 50 ml/day in 2 consecutive days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of AEs and laboratory, ECG, vital sign abnormalities of LF-PB 10 mg, 20 mg, and 30 mg</measure>
    <time_frame>12 weeks after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability of LF-PB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effects of LF-PB 10, 20, and 30 mg on the daily volume of lymph collected from the drain</measure>
    <time_frame>12 weeks after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>daily volume of lymph collected from the drain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of complications related to lymphorrhea</measure>
    <time_frame>12 weeks after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>effect of LF-PB 10, 20 and 30 mg on complications related to lymphorrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile (Cmax, Tmax, AUC0-t and possibly AUC0-inf and T1/2) of LF-PB 10, 20 and 30 mg</measure>
    <time_frame>12 weeks after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters</description>
  </secondary_outcome>
  <other_outcome>
    <measure>correlation between LF-PB exposures and efficacy after the administration of LF-PB 10 mg, 20 mg, and 30 mg</measure>
    <time_frame>12 weeks after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>correlation between exposure of the drug and efficacy</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lymphorrhea</condition>
  <arm_group>
    <arm_group_label>LF-PB 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 IM injections = placebo + 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LF-PB 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 IM injections = placebo + 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LF-PB 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 IM injections = 10 mg + 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 IM injections of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LF-PB and Placebo</intervention_name>
    <arm_group_label>LF-PB 10 mg</arm_group_label>
    <arm_group_label>LF-PB 20 mg</arm_group_label>
    <other_name>extended-release of octreotide and placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LF-PB</intervention_name>
    <arm_group_label>LF-PB 30 mg</arm_group_label>
    <other_name>LF-PB 10 mg and LF-PB 20 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female aged 18 to 80 years inclusive

          2. Body mass index (BMI) ≥18 kg/m2

          3. Signed informed consent form

          4. Diagnosis of BC

          5. Undergoing breast surgery with ALND Note:  Collagen powder or fibrin sealant are not
             permitted.

          6. Negative serum pregnancy test for women of childbearing potential Note:  Female
             patients of child-bearing potential should be advised to use adequate contraception
             if necessary during treatment with octreotide.

          7. AST and alanine aminotransferase ALT &lt;1.5 x the upper limit of normal

          8. Ability to fully understand all study procedures and to comply with study visits
             scheduled for the duration of the study.

        Exclusion Criteria:

          1. Presence of any of the following conditions:

               1. Previous axillary surgery on the same armpit undergoing surgery in this study

               2. Previous chemotherapy or radiotherapy within five years from study drug
                  administration

               3. Previous neoadjuvant therapy

               4. Recurrent BC on the same breast undergoing surgery in this study

               5. Diabetes

               6. Cholelithiasis

               7. Hypothyroidism. If patient is being administered Euritox/ Levothyroxine (or
                  analogues) and levels of T3, T4 and TSH are confirmed to be within the normal
                  ranges at screening, the patient can be enrolled in this study.

               8. Hepatitis

               9. Pregnant or lactating

              10. Human immunodeficiency virus or hepatitis B or C by screening serology

          2. History of radiotherapy on the same breast or armpit undergoing surgery in this
             study.

          3. History of anaphylaxis to study drug

          4. Ascertained or presumptive hypersensitivity to the active principle and/or the
             ingredients of the study drug formulation

          5. QTc interval extension at screening or baseline &gt; 450 msec (as the mean of 3
             consecutive readings 5 minutes apart)

          6. Presence of any disease or use of concomitant medication known to increase the QT
             interval (see Appendix 2 for a list of such compounds)

          7. Clinically significant or relevant abnormal medical history, vital sign, physical
             examination, ECG, or laboratory evaluation finding

          8. Current or recurrent disease that could affect the results of the clinical or
             laboratory assessments required for the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Carcoforo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Chirurgica, Azienda Ospedaliero-Universitaria Arcispedale &quot;S. Anna&quot; Ferrara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Bettica, MD PhD</last_name>
    <phone>0039 02 6443</phone>
    <phone_ext>2584</phone_ext>
    <email>p.bettica@italfarmaco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Humanitas Centro Catanese di Oncologia Dipartimento di Oncologia -Chirurgia Oncologica Generale</name>
      <address>
        <city>Via V.E. Dabormida, 64</city>
        <state>Catania</state>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaetano Castiglione, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gaetano Castiglione, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione per la Ricerca e la Cura dei Tumori &quot;Tommaso Campanella&quot; Unità Operativa Complessa CRR per il Counselling Genetico e le Terapie Innovative in Oncologia Medica</name>
      <address>
        <city>Viale Europa-Loc. Germaneto</city>
        <state>Catanzaro</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierfrancesco Tassone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierfrancesco Tassone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera OIRM Sant'Anna Dipartimento Funzionale di Oncologia - Breast Unit</name>
      <address>
        <city>Corso Spezia, 60 Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrado De Sanctis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Corrado De Sanctis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliero Universitaria San Martino di Genova - IST Genova Dipartimento Chirurgia Ospedaliera - Semeiotica Chirurgica e Chirurgia Senologica</name>
      <address>
        <city>L.go Rosanna Benzi,10 Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari Chirurgia Generale Universitaria &quot;G.Marinaccio&quot;</name>
      <address>
        <city>Piazza Giulio Cesare 11 Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Margari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Margari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Di Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Roncella, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manuela Roncella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita` Campus Bio-medico di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Altomare, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vittorio Altomare, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della Sofferenza - Istituto di Ricovero e Cura a Carattere Scientifico Opera di San Pio da Pietrelcina</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Murgo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Murgo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - IRCC Candiolo D.O. di Ginecologia Oncologica</name>
      <address>
        <city>Strada Provinciale 142 Km 3.95- Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riccardo Ponzone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Riccardo Ponzone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma Dipartimento Clinica Chirurgica e Terapia Chirurgica</name>
      <address>
        <city>Via Gramsci, 14 Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dante Palli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dante Palli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione Giovanni Pascale Dipartimento di Senologia - Struttura Complessa Oncologia Medica Senologica</name>
      <address>
        <city>Via Mariano Semmola Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelino De Laurentiis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michelino De Laurentiis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico di Modena Unità Semplice di Senologia</name>
      <address>
        <city>Via Pozzo 71, Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Tazzioli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Tazzioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Ferrara c/o Ospedale di Cona Sezione di Clinica Chirurgica</name>
      <address>
        <city>Vial Aldo Moro 8, Cona-Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Carcoforo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Carcoforo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 24, 2013</lastchanged_date>
  <firstreceived_date>December 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
